OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Mestre-Ferrandiz, J., Garau, M., O'Neill, P. and Sussex, J.

Consulting Report
November 2010

This report examines the effect of the European Union’s 1999 Regulation on Orphan Medicinal Products (OMPs) on the European economy and society.  This study collected data on several indicators of activity, completed a confidential survey of companies developing OMP, concluded four case studies and undertook a literature review.  The result is a rich tableau of data and information that describe the effects of the OMP Regulation in some detail.  Findings include the following.

O'Neill, P.

Monograph
November 2010

In December 2006, the National Institute for Health and Clinical Excellence (NICE) issued guidance for preventing and managing overweight and obesit. Recommendations are step-wise, starting with lifestyle changes and progressing through medicine to bariatric surgery. The guidance recommends that patients considered for bariatric surgery have either a BMI of 40 or more, or a BMI over 35 with an associated condition such as diabetes. Costing guidelines are included in the guidance.

Sussex, J., Shah, K. and Butler, J.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in Australia. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and implications of central purchasing for economic efficiency.

Sussex, J. and Shah, K.

Consulting Report
October 2010

This research reviews how vaccines other than for travel or influenza are evaluated, procured and delivered in the UK. It includes observations as to whether and how the economic assessment process differs for vaccines compared to curative pharmaceutical products and the implications of the current pricing approach.

Garau, M., Shah, K., Mason, A.R., Wang, Q., Towse, A. and Drummond, M.F.

Research Paper
October 2010

Current methods for constructing quality adjusted life year (QALY) measurements may be deficient for cancer patients in three respects: descriptions of health state, valuation of health state, and the source of values upon which measures are based.

Existing measures of health are either not sensitive enough or not attuned to cancer patients’ actual preferences.  For example, evidence suggests that the EQ 5D instrument does not capture the small changes in health that often are very important to cancer patients.

Mestre-Ferrandiz, J., Puig-Peiro, R. and Towse, A.

Consulting Report
October 2010

Ten member companies of the EFPIA HTA Task Force commissioned OHE consulting to provide research, data and analysis that would enable EFPIA both to support and develop its policy position and to contribute positively to the emerging dialogue around the development of HTA within Europe.

This research was designed to:

Sharma, P. and Towse, A.

Occasional Paper
October 2010

Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to develop comprehensive proposals by the end of 2012 for addressing the situation. This Paper is meant to provide input into those policy discussions.

The paper reviews AMR’s implications for the burden of disease, the causes of AMR, the current state of the antibiotic development pipeline and the reasons antibiotic R&D has been de-emphasised by biopharmaceutical companies.

Office of Health Economics and RAND Europe

Occasional Paper
October 2010

Research spillovers may exist when research by one organisation creates increased output for other organisations that operate in the same or another sector of the economy.  Both the mechanisms and the ultimate value of this transfer of ideas, knowledge or know-how still are not fully understood and virtually all such research on spillovers has been focused outside the UK.  Given current constraints on public, charitable and private research funding, enhancing spillovers may become an important objective in UK science and technology policy.

Garber, A.M.

Monograph
September 2010

The speaker for the OHE’s 17th Annual Lecture was Dr Alan Garber, Director both of Stanford University’s Center for Health Policy and its Center for Primary Care and Outcomes Research at the School of Medicine. His remarks focused on the national health care legislation enacted in March 2010 in the US from a unique perspective – as a practicing professor of medicine, one of the world’s leading health economists, and an expert in health care policy.  His overview touched on several of the key issues raised by the new law that relate to coverage, cost, and quality.

Sussex, J.

Seminar Briefing
August 2010

Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included representatives of the pharmaceutical industry, health technology assessment bodies and academic economists.

Pages